Category - Feature

Feature

PharmAust readies pivotal trial in Australia to treat cancer in dogs

PharmAust (ASX:PAA) is gearing up to begin a pivotal Phase 2 study in Australia with its lead veterinary drug candidate, monepantel, for the treatment of lymphoma in canines, which if successful, could open the door to...

August 12, 2019

Feature

Theralase Phase 2 NMIBC clinical study could support marketing application

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) has designed its Phase 2 clinical study in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) based on FDA industry guidance issued in February 2018.

August 6, 2019

Feature

Hepion Pharmaceuticals’ CEO Robert Foster discusses CRV431’s potential in NASH

Hepion Pharmaceuticals (NASDAQ:HEPA), which recently changed its name from ContraVir Pharmaceuticals, is developing targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic...

July 30, 2019

Feature

PharmaCyte’s Cell-in-a-Box encapsulation technology targeting cancer, diabetes

PharmaCyte Biotech (OTCQB:PMCB) is developing cellular therapies for its lead pancreatic cancer program and for diabetes that are based on a proprietary cellulose-based live cell encapsulation technology known as a Cell...

July 23, 2019

Feature

Stifel analyst discusses emerging NASH therapeutic space

As a director and senior analyst covering the biotechnology sector at Stifel, Derek Archila combines analytic ability and industry experience. He has held executive positions covering biotechnology and specialty...

July 12, 2019

Feature

Ocutrx augmented reality headset helping AMD patients see clearly

California-based Ocutrx Vision Technologies has developed an augmented reality (AR) headset that helps age-related macular degeneration (AMD) patients overcome severe and devastating vision loss.

July 9, 2019

Feature

Helius Medical rolling out PoNS treatment for mmTBI in Canada

Helius Medical Technologies (NASDAQ:HSDT; TSX:HSM) is transitioning from a development- to commercial-stage company as it rolls out its Health Canada-cleared PoNS medical device for the treatment of chronic balance...

July 2, 2019

Feature

Chardan president, Jonas Grossman, talks SPACs

By Abby Hardy As president of Chardan, an independent, global investment bank specializing in healthcare, disruptive technologies, and special purpose acquisition companies (SPACs), Jonas Grossman takes a worldwide view...

June 25, 2019

Feature

Zenabis sets sights on becoming leading cannabis producer

By Len Zehr Despite being a new entrant in the cannabis market, Zenabis Global (TSX:ZENA) is making huge strides to become one of the largest licensed producers of medical and adult-use recreational cannabis in Canada...

June 11, 2019

Feature

Oragenics developing novel therapeutics using synthetic bacteria

By Abby Hardy Oragenics (NYSE American: OGEN) is leveraging its synthetic biology platforms to address two significant unmet medical needs: oral mucositis (OM) and multi drug-resistant (MDR) bacterial infections...

May 28, 2019

Category - Feature

PharmAust readies pivotal trial in Australia to treat cancer in dogs

Theralase Phase 2 NMIBC clinical study could support marketing application

Hepion Pharmaceuticals’ CEO Robert Foster discusses CRV431’s potential in NASH

PharmaCyte’s Cell-in-a-Box encapsulation technology targeting cancer, diabetes

Stifel analyst discusses emerging NASH therapeutic space

Ocutrx augmented reality headset helping AMD patients see clearly

Helius Medical rolling out PoNS treatment for mmTBI in Canada

Chardan president, Jonas Grossman, talks SPACs

Zenabis sets sights on becoming leading cannabis producer

Oragenics developing novel therapeutics using synthetic bacteria

General

More